关键词: 晚期上皮性卵巢癌, 初始肿瘤细胞减灭术, 间歇性肿瘤细胞减灭术, 新辅助化疗

Abstract: The rate of NACT use has increased annually for advanced ovarian cancer in clinical practice. Neoadjuvant chemotherapy（NACT）for ovarian cancer is still controversial for many years，although patients received NACT followed by interval cytoreductive surgery had equivalent progression-free survival and overall survival compared with primary cytoreductive surgery among women with advanced stage ovarian cancer, with less surgical morbidity in randomized control studies.At present，the newly diagnosed ovarian cancer patients should be evaluated by gynecological oncologists and/or multi-disciplinary assessment if necessary.Primary tumor reductive surgery should be attempted priority to achieve satisfactory tumor resection after evaluation.However，neoadjuvant chemotherapy followed by interval tumor reductive surgery is an alternative approach for unresectable tumor or reductive surgery is not feasible.

Key words: advanced epithelial ovarian cancer, primary cytoreductive surgery, interval debulking surgery, neoadjuvant chemotherapy